Myocarditis Clinical Trial
Official title:
The Efficacy and Mechanism of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy After Myocarditis
Evaluating the long-term therapeutic effects of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study
Inflammatory cardiomyopathy is the chronic stage of myocarditis, which is associated with poor cardiovascular outcome and poor prognosis.Inflammatory cardiomyopathy is also one of the common causes of heart failure. Actually, the treatment and prognosis of inflammatory cardiomyopathy remain challenging clinical issues that often have frustrating consequences. So far, there is no specific treatment for inflammatory cardiomyopathy. Hydroxychloroquine is a drug that can effectively inhibit inflammation and has been used in many inflammatory diseases in the past. Our previous basic research has proved that hydroxychloroquine can effectively treat experimental autoimmune myocarditis.Therefore, multicenter large randomized controlled trials are needed to verify the therapeutic effects of hydroxychloroquine on patients with inflammatory cardiomyopathy. Patients with inflammatory cardiomyopathy after acute myocarditis confirmed by biopsy received standard drug treatment for heart failure. These patients whose cardiac function could not be improved for a long time were randomly assigned (1:1) to hydroxychloroquine group (hydroxychloroquine and glucocorticoid) and glucocorticoid group (glucocorticoid alone). The clinical benefit will be measured with respect to absolute increase in LVEF and decrease in hs-cTnI and NT-proBNP of immunosuppressive treatment with hydroxychloroquine and prednisolone compared to prednisolone alone at long-term follow-up (6, 12, 18, 24, 36 months). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
| Not yet recruiting |
NCT04085718 -
FDG-PET/CT Images Comparing to MRI and Endomyocardial Biopsy in Myocarditis
|
||
| Enrolling by invitation |
NCT05610423 -
Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway
|
||
| Active, not recruiting |
NCT05195645 -
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
|
Phase 2 | |
| Recruiting |
NCT05184114 -
Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance
|
N/A | |
| Recruiting |
NCT04612296 -
The Heart Hive - Cardiomyopathy Study
|
||
| Recruiting |
NCT04673409 -
CMR Imaging of Autoimmune Diseases
|
||
| Recruiting |
NCT05295290 -
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
|
Phase 4 | |
| Completed |
NCT03777839 -
PET-FDG in Myocarditis
|
||
| Completed |
NCT06447935 -
Acute Eosinophilic Myocarditis International Registry
|
||
| Not yet recruiting |
NCT05125965 -
Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy
|
N/A | |
| Active, not recruiting |
NCT04444128 -
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
|
||
| Recruiting |
NCT06158698 -
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
|
Phase 3 | |
| Recruiting |
NCT05282498 -
Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)
|
||
| Recruiting |
NCT05288426 -
Myocarditis Post Vaccination or Multi System Inflammatory Syndrome
|
||
| Recruiting |
NCT03801681 -
ARrhythmias in MYocarditis
|
||
| Recruiting |
NCT06116084 -
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
|
N/A | |
| Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|
||
| Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
| Recruiting |
NCT06409585 -
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
|